Pruritus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 163 Published: March 31, 2022 Report Code: GMDGDHC22113IDB

Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.

The Pruritus- Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects.

Key Targets in the Pruritus Pipeline Drugs Market

The key targets in the Pruritus pipeline drugs market are Kappa Type Opioid Receptor, Sodium Channel Protein Type 10 Subunit Alpha, Sodium Channel Protein Type 3 Subunit Alpha, Sphingosine 1-Phosphate Receptor 1, Substance P Receptor, Tyrosine Protein Kinase JAK1, Voltage Dependent T Type Calcium Channel, and Voltage Dependent T Type Calcium Channel Subunit Alpha 1G among others.

Pruritus Pipeline Drugs Market, by Targets

Pruritus Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Pruritus Pipeline Drugs Market

The key mechanisms of action in the Pruritus pipeline drugs market are Kappa Type Opioid Receptor Agonist, Mu Type Opioid Receptor Antagonist, Ileal Sodium/Bile Acid Cotransporter Inhibitor, Mas Related G Protein Coupled Receptor Member X2 Antagonist, Sodium Channel Protein Type 9 Subunit Alpha Blocker, and 5-Hydroxytryptamine Receptor 2A Antagonist.

Pruritus Pipeline Drugs Market, by MoA

Pruritus Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Pruritus Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Pruritus pipeline drugs market are Oral, Subcutaneous, Intravenous, Topical, Inhalational, Buccal, Nasal, and Rectal.

PruritusPipeline Drugs Market Analysis, by RoA

PruritusPipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Pruritus Pipeline Drugs Market

The key molecule types in the Pruritus pipeline drugs market are Monoclonal Antibody, Small Molecule, Synthetic Peptide, Peptide and Biologic among others.

Pruritus Pipeline Drugs Market, by Molecule Type

Pruritus Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the Pruritus Pipeline Drugs Market

The major companies in the Pruritus pipeline drugs market are Cara Therapeutics Inc, Amgen Inc, Asana BioSciences LLC, Avior Bio Inc, Toray Industries Inc, Trevi Therapeutics Inc, 9 Meters Biopharma Inc, AfaSci Inc, Akaal Pharma Pty Ltd, and Albireo Pharma Inc among others.

Pruritus Pipeline Drugs Market, by Major Companies

Pruritus Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Pruritus Pipeline Drugs Market Overview

Key Targets Kappa Type Opioid Receptor, Sodium Channel Protein Type 10 Subunit Alpha, Sodium Channel Protein Type 3 Subunit Alpha, Sphingosine 1-Phosphate Receptor 1, Substance P Receptor, Tyrosine Protein Kinase JAK1, Voltage Dependent T Type Calcium Channel, and Voltage Dependent T Type Calcium Channel Subunit Alpha 1G
Key Mechanisms of action Kappa Type Opioid Receptor Agonist, Mu Type Opioid Receptor Antagonist, Ileal Sodium/Bile Acid Cotransporter Inhibitor, Mas Related G Protein Coupled Receptor Member X2 Antagonist, Sodium Channel Protein Type 9 Subunit Alpha Blocker, and 5-Hydroxytryptamine Receptor 2A Antagonist
Key Routes of Administration Oral, Subcutaneous, Intravenous, Topical, Inhalational, Buccal, Nasal, and Rectal
Key molecule types Monoclonal Antibody, Small Molecule, Synthetic Peptide, Peptide and Biologic
Major companies Cara Therapeutics Inc, Amgen Inc, Asana BioSciences LLC, Avior Bio Inc, Toray Industries Inc, Trevi Therapeutics Inc, 9 Meters Biopharma Inc, AfaSci Inc, Akaal Pharma Pty Ltd, and Albireo Pharma Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus
  • The pipeline guide reviews pipeline therapeutics for Pruritus by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pruritus therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pruritus therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Pruritus

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pruritus
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

9 Meters Biopharma Inc

AfaSci Inc

Akaal Pharma Pty Ltd

Albireo Pharma Inc

Amgen Inc

AntalGenics SL

AOBiome LLC

Asana BioSciences LLC

Avior Bio Inc

BioArdis LLC

Biomimetix JV LLC

Cara Therapeutics Inc

Chugai Pharmaceutical Co Ltd

Clexio Biosciences Ltd

DermaXon LLC

DongKoo Bio & Pharma Co Ltd

ELORAC Inc

Escient Pharmaceuticals Inc

Evommune Inc

Genu Pharma Co Ltd

GlaxoSmithKline Plc

Jiangsu Hengrui Medicine Co Ltd

Kiniksa Pharmaceuticals Ltd

Kissei Pharmaceutical Co Ltd

Lumosa Therapeutics Co Ltd

MC2 Therapeutics AS

Mirum Pharmaceuticals Inc

Neurim Pharmaceuticals Ltd

Patagonia Pharmaceuticals LLC

Peptide Logic LLC

Pfizer Inc

RaQualia Pharma Inc

Regeneron Pharmaceuticals Inc

Saniona AB

Sanwa Kagaku Kenkyusho Co Ltd

Shanton Pharma Co Ltd

Sichuan Haisco Pharmaceutical Co Ltd

Sienna Biopharmaceuticals Inc

Sunny Pharmtech Inc

Suzhou Connect Biopharmaceuticals Ltd

Teikoku Pharma USA Inc

Tioga Pharmaceuticals Inc

Titan Pharmaceuticals Inc

Toray Industries Inc

Trevi Therapeutics Inc

Vivozon Inc

YIRUI Pharmaceutical Technology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pruritus – Overview

Pruritus – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pruritus – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pruritus – Companies Involved in Therapeutics Development

9 Meters Biopharma Inc

AfaSci Inc

Akaal Pharma Pty Ltd

Albireo Pharma Inc

Amgen Inc

AntalGenics SL

AOBiome LLC

Asana BioSciences LLC

Avior Bio Inc

BioArdis LLC

Biomimetix JV LLC

Cara Therapeutics Inc

Chugai Pharmaceutical Co Ltd

Clexio Biosciences Ltd

DermaXon LLC

DongKoo Bio & Pharma Co Ltd

ELORAC Inc

Escient Pharmaceuticals Inc

Evommune Inc

Genu Pharma Co Ltd

GlaxoSmithKline Plc

Jiangsu Hengrui Medicine Co Ltd

Kiniksa Pharmaceuticals Ltd

Kissei Pharmaceutical Co Ltd

Lumosa Therapeutics Co Ltd

MC2 Therapeutics AS

Mirum Pharmaceuticals Inc

Neurim Pharmaceuticals Ltd

Patagonia Pharmaceuticals LLC

Peptide Logic LLC

Pfizer Inc

RaQualia Pharma Inc

Regeneron Pharmaceuticals Inc

Saniona AB

Sanwa Kagaku Kenkyusho Co Ltd

Shanton Pharma Co Ltd

Sichuan Haisco Pharmaceutical Co Ltd

Sienna Biopharmaceuticals Inc

Sunny Pharmtech Inc

Suzhou Connect Biopharmaceuticals Ltd

Teikoku Pharma USA Inc

Tioga Pharmaceuticals Inc

Titan Pharmaceuticals Inc

Toray Industries Inc

Trevi Therapeutics Inc

Vivozon Inc

YIRUI Pharmaceutical Technology Co Ltd

Pruritus – Drug Profiles

abrocitinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

AG-1529 – Drug Profile

Product Description

Mechanism Of Action

AKP-11 – Drug Profile

Product Description

Mechanism Of Action

History of Events

AM-6120 – Drug Profile

Product Description

Mechanism Of Action

AMG-8379 – Drug Profile

Product Description

Mechanism Of Action

asimadoline – Drug Profile

Product Description

Mechanism Of Action

History of Events

ASN-008 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ASN-009 – Drug Profile

Product Description

Mechanism Of Action

AV-104 – Drug Profile

Product Description

Mechanism Of Action

History of Events

B-244 – Drug Profile

Product Description

Mechanism Of Action

History of Events

bepotastine SR – Drug Profile

Product Description

Mechanism Of Action

BMX-010 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CBP-174 – Drug Profile

Product Description

Mechanism Of Action

History of Events

detomidine – Drug Profile

Product Description

Mechanism Of Action

difelikefalin – Drug Profile

Product Description

Mechanism Of Action

History of Events

DKB-19003 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Drugs to Block Cav3 and Nav for Pruritus – Drug Profile

Product Description

Mechanism Of Action

dupilumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

DX-412 – Drug Profile

Product Description

Mechanism Of Action

History of Events

EP-547 – Drug Profile

Product Description

Mechanism Of Action

History of Events

EVO-103 – Drug Profile

Product Description

Mechanism Of Action

HPI-1201 – Drug Profile

Product Description

Mechanism Of Action

History of Events

HSK-21542 – Drug Profile

Product Description

Mechanism Of Action

KNV-0969 – Drug Profile

Product Description

Mechanism Of Action

linerixibat – Drug Profile

Product Description

Mechanism Of Action

History of Events

LT-5001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

MC-225 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibody Conjugate to Agonize Kappa Opioid Receptor for Dermatosis, Osteoarthritis Pain and Uremic Pruritus – Drug Profile

Product Description

Mechanism Of Action

History of Events

MRGPRX2 Antagonist – Drug Profile

Product Description

Mechanism Of Action

nalbuphine hydrochloride ER – Drug Profile

Product Description

Mechanism Of Action

History of Events

nalfurafine hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

naloxone hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

nemolizumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

NeuP-12 – Drug Profile

Product Description

Mechanism Of Action

odevixibat – Drug Profile

Product Description

Mechanism Of Action

History of Events

opiranserin – Drug Profile

Product Description

Mechanism Of Action

PATN-02 – Drug Profile

Product Description

Mechanism Of Action

pegcantratinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

Peptides to Target TRPV1 for Pain and Pruritus – Drug Profile

Product Description

Mechanism Of Action

phenylbutyrate – Drug Profile

Product Description

Mechanism Of Action

PR-38 – Drug Profile

Product Description

Mechanism Of Action

RDD-1609 – Drug Profile

Product Description

Mechanism Of Action

SAN-711 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SAP-002 – Drug Profile

Product Description

Mechanism Of Action

SHR-0410 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SK-1405 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Agonize KOR1 for Pruritus – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Block Nav1.8 Sodium Channel for Pain And Pruritis – Drug Profile

Product Description

Mechanism Of Action

History of Events

TPU-010 – Drug Profile

Product Description

Mechanism Of Action

vixarelimab – Drug Profile

Product Description

Mechanism Of Action

History of Events

volixibat potassium – Drug Profile

Product Description

Mechanism Of Action

History of Events

YR-007 – Drug Profile

Product Description

Mechanism Of Action

Pruritus – Dormant Projects

Pruritus – Discontinued Products

Pruritus – Product Development Milestones

Featured News & Press Releases

Mar 28, 2022: Cara Therapeutics announces Oral KORSUVA (difelikefalin) improves itch and inflammatory biomarkers in atopic dermatitis patients with moderate-to-severe pruritus

Mar 08, 2022: Cara Therapeutics announces oral KORSUVA (difelikefalin) data selected for late-breaking presentation at 2022 American Academy of Dermatology Annual Meeting

Feb 25, 2022: Kapruvia receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients

Feb 22, 2022: AOBiome Therapeutics’ topical biotherapeutic B244 demonstrated positive Phase 2b results from its 547 patient trial for both Pruritus (Itch) and appearance in its 547 patient Phase 2b trial of Atopic Dermatitis (Eczema)

Feb 02, 2022: Trevi concludes enrolment of Phase IIb/III itch trial in prurigo nodularis

Jan 10, 2022: Cara Therapeutics announces Difelikefalin (KORSUVA) Injection achieves positive topline results in Phase 3 clinical study in Japan for the treatment of pruritus in hemodialysis patients

Jan 10, 2022: Cara Therapeutics announces Difelikefalin (KORSUVA) Injection achieves positive topline results in Phase 3 clinical study in Japan for the treatment of pruritus in hemodialysis patients

Jan 05, 2022: Enteris BioPharma highlights 2021 achievements and 2022 Outlook

Jan 05, 2022: Albireo increases 2021 Bylvay (odevixibat) sales guidance

Dec 20, 2021: Cara Therapeutics announces CMS grants TDAPA to KORSUVA (difelikefalin) injection

Dec 13, 2021: Albireo presenting new Bylvay (odevixibat) Data at NASPGHAN 2021

Nov 16, 2021: AOBiome achieves landmark recruitment goal in largest clinical trial ever powered by a live topical biotherapeutic

Nov 15, 2021: Trevi Therapeutics to present at 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases

Nov 12, 2021: Albireo announces new phase 3 data for Bylvay (odevixibat) in PFIC and first reveal of new next generation bile acid modulator data at AASLD The Liver Meeting 2021

Nov 05, 2021: Titan announces upcoming TP-2021 Implant data presentation at Neuroscience 2021

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Pruritus, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pruritus – Pipeline by 9 Meters Biopharma Inc, 2022

Pruritus – Pipeline by AfaSci Inc, 2022

Pruritus – Pipeline by Akaal Pharma Pty Ltd, 2022

Pruritus – Pipeline by Albireo Pharma Inc, 2022

Pruritus – Pipeline by Amgen Inc, 2022

Pruritus – Pipeline by AntalGenics SL, 2022

Pruritus – Pipeline by AOBiome LLC, 2022

Pruritus – Pipeline by Asana BioSciences LLC, 2022

Pruritus – Pipeline by Avior Bio Inc, 2022

Pruritus – Pipeline by BioArdis LLC, 2022

Pruritus – Pipeline by Biomimetix JV LLC, 2022

Pruritus – Pipeline by Cara Therapeutics Inc, 2022

Pruritus – Pipeline by Chugai Pharmaceutical Co Ltd, 2022

Pruritus – Pipeline by Clexio Biosciences Ltd, 2022

Pruritus – Pipeline by DermaXon LLC, 2022

Pruritus – Pipeline by DongKoo Bio & Pharma Co Ltd, 2022

Pruritus – Pipeline by ELORAC Inc, 2022

Pruritus – Pipeline by Escient Pharmaceuticals Inc, 2022

Pruritus – Pipeline by Evommune Inc, 2022

Pruritus – Pipeline by Genu Pharma Co Ltd, 2022

Pruritus – Pipeline by GlaxoSmithKline Plc, 2022

Pruritus – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Pruritus – Pipeline by Kiniksa Pharmaceuticals Ltd, 2022

Pruritus – Pipeline by Kissei Pharmaceutical Co Ltd, 2022

Pruritus – Pipeline by Lumosa Therapeutics Co Ltd, 2022

Pruritus – Pipeline by MC2 Therapeutics AS, 2022

Pruritus – Pipeline by Mirum Pharmaceuticals Inc, 2022

Pruritus – Pipeline by Neurim Pharmaceuticals Ltd, 2022

Pruritus – Pipeline by Patagonia Pharmaceuticals LLC, 2022

Pruritus – Pipeline by Peptide Logic LLC, 2022

Pruritus – Pipeline by Pfizer Inc, 2022

Pruritus – Pipeline by RaQualia Pharma Inc, 2022

Pruritus – Pipeline by Regeneron Pharmaceuticals Inc, 2022

Pruritus – Pipeline by Saniona AB, 2022

Pruritus – Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, 2022

Pruritus – Pipeline by Shanton Pharma Co Ltd, 2022

Pruritus – Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, 2022

Pruritus – Pipeline by Sienna Biopharmaceuticals Inc, 2022

Pruritus – Pipeline by Sunny Pharmtech Inc, 2022

Pruritus – Pipeline by Suzhou Connect Biopharmaceuticals Ltd, 2022

Pruritus – Pipeline by Teikoku Pharma USA Inc, 2022

Pruritus – Pipeline by Tioga Pharmaceuticals Inc, 2022

Pruritus – Pipeline by Titan Pharmaceuticals Inc, 2022

Pruritus – Pipeline by Toray Industries Inc, 2022

Pruritus – Pipeline by Trevi Therapeutics Inc, 2022

Pruritus – Pipeline by Vivozon Inc, 2022

Pruritus – Pipeline by YIRUI Pharmaceutical Technology Co Ltd, 2022

Pruritus – Dormant Projects, 2022

Pruritus – Dormant Projects, 2022 (Contd..1)

Pruritus – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Pruritus, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently Asked Questions

Enquire Before Buying
$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.